Suppr超能文献

亚太地区腹腔内感染患者分离的革兰氏阴性杆菌的抗生素药敏流行病学和趋势,2010-2013 年。

Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013.

机构信息

Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Royal Perth Hospital, Perth, WA, Australia.

出版信息

Int J Antimicrob Agents. 2017 Jun;49(6):734-739. doi: 10.1016/j.ijantimicag.2017.01.030. Epub 2017 Apr 20.

Abstract

This study was conducted to investigate the epidemiology and antimicrobial susceptibility patterns of Gram-negative bacilli (GNB) isolated from intra-abdominal infections (IAIs) in the Asia-Pacific region (APR) from 2010-2013. A total of 17 350 isolates were collected from 54 centres in 13 countries in the APR. The three most commonly isolated GNB were Escherichia coli (46.1%), Klebsiella pneumoniae (19.3%) and Pseudomonas aeruginosa (9.8%). Overall, the rates of extended-spectrum β-lactamase (ESBL)-producing E. coli and K. pneumoniae were 38.2% and 24.3%, respectively, and they were highest in China (66.6% and 38.7%, respectively), Thailand (49.8% and 36.5%, respectively) and Vietnam (47.9% and 30.4%, respectively). During 2010-2013, the rates of ESBL-producing E. coli and K. pneumoniae isolates causing community-associated (CA) IAIs (collected <48 h after admission) were 26.0% and 13.5%, respectively, and those causing hospital-associated (HA) IAIs were 48.0% and 30.6%, respectively. Amikacin, ertapenem and imipenem were the most effective agents against ESBL-producing isolates. Piperacillin/tazobactam displayed good in vitro activity (91.4%) against CA ESBL-producing E. coli. For other commonly isolated Enterobacteriaceae, fluoroquinolones, cefepime and carbapenems exhibited better in vitro activities than third-generation cephalosporins. Amikacin possessed high in vitro activity against all GNB isolates (>80%) causing IAIs, except for Acinetobacter calcoaceticus-baumannii (ACB) complex (30.9% for HA-IAI isolates). All of the antimicrobial agents tested exhibited <45% in vitro activity against ACB complex. Antimicrobial resistance is a persistent threat in the APR and continuous monitoring of evolutionary trends in the susceptibility patterns of GNB causing IAIs in this region is mandatory.

摘要

本研究旨在调查 2010-2013 年亚太地区(APR)腹腔内感染(IAI)分离的革兰氏阴性菌(GNB)的流行病学和抗菌药物敏感性模式。从 APR 的 13 个国家的 54 个中心共收集了 17350 株分离株。分离出的三种最常见的革兰氏阴性菌是大肠埃希菌(46.1%)、肺炎克雷伯菌(19.3%)和铜绿假单胞菌(9.8%)。总体而言,产超广谱β-内酰胺酶(ESBL)的大肠埃希菌和肺炎克雷伯菌的检出率分别为 38.2%和 24.3%,检出率最高的是中国(分别为 66.6%和 38.7%)、泰国(分别为 49.8%和 36.5%)和越南(分别为 47.9%和 30.4%)。2010-2013 年,社区获得性(CA)IAI(入院<48 小时采集)产 ESBL 的大肠埃希菌和肺炎克雷伯菌的分离率分别为 26.0%和 13.5%,而医院获得性(HA)IAI 产 ESBL 的分离率分别为 48.0%和 30.6%。阿米卡星、厄他培南和亚胺培南是治疗产 ESBL 株的最有效药物。哌拉西林/他唑巴坦对 CA 产 ESBL 的大肠埃希菌具有良好的体外活性(91.4%)。对于其他常见的肠杆菌科细菌,氟喹诺酮类、头孢吡肟和碳青霉烯类的体外活性优于第三代头孢菌素。除鲍曼不动杆菌复合体(ACB)外(HA-IAI 分离株为 30.9%),阿米卡星对引起 IAI 的所有 GNB 分离株(>80%)均具有较高的体外活性。所有测试的抗菌药物对 ACB 复合体的体外活性均<45%。抗菌药物耐药性是 APR 地区持续存在的威胁,必须对该地区引起 IAI 的 GNB 敏感性模式的演变趋势进行持续监测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验